Last reviewed · How we verify
Generic tacrolimus
At a glance
| Generic name | Generic tacrolimus |
|---|---|
| Also known as | Sandoz |
| Sponsor | Sandoz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
- Belatacept in Heart Transplantation (PHASE2)
- To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (PHASE4)
- Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients (PHASE4)
- Bioequivalence Study of Tacrolimus in Healthy Volunteers (PHASE1)
- Envarsus in Delayed Graft Function (E-DGF) (PHASE4)
- Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic tacrolimus CI brief — competitive landscape report
- Generic tacrolimus updates RSS · CI watch RSS
- Sandoz portfolio CI